BIOMARIN PHARMACEUTICAL INC Cash and Cash Equivalents
BIOMARIN PHARMACEUTICAL INC (BMRN) had Cash and Cash Equivalents of $874.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $874.00M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $2.22B.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $1.31B.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $1.25B.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $874.00M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.22B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $1.31B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.25B 10-Q · filed 2025-10-28 |
| 2025-06-30 | $1.21B 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.05B 10-Q · filed 2025-05-02 |
| 2024-12-31 | $942.84M 10-K · filed 2026-02-26 |
| 2024-09-30 | $675.45M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $972.15M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $747.00M 10-Q · filed 2024-04-26 |
| 2023-12-31 | $755.13M 10-K · filed 2025-02-24 |
| 2023-09-30 | $785.41M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $694.38M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $580.07M 10-Q · filed 2023-04-28 |
| 2022-12-31 | $724.53M 10-K · filed 2024-02-26 |
| 2022-09-30 | $761.51M 10-Q · filed 2022-10-28 |
| 2022-06-30 | $619.80M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $605.44M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $587.28M 10-K · filed 2023-02-27 |
| 2021-09-30 | $617.14M 10-Q · filed 2021-10-29 |
| 2021-06-30 | $641.53M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $667.31M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $649.16M 10-K · filed 2022-02-25 |
| 2020-09-30 | $1.02B 10-Q · filed 2020-11-06 |
| 2020-06-30 | $818.90M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $476.63M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $437.45M 10-K · filed 2021-02-26 |
| 2019-09-30 | $423.22M 10-Q/A · filed 2019-11-04 |
| 2019-06-30 | $307.58M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $364.37M 10-Q · filed 2020-05-01 |
| 2018-12-31 | $493.98M 10-Q · filed 2020-08-05 |
| 2018-09-30 | $882.18M 10-Q/A · filed 2019-11-04 |
| 2018-06-30 | $427.41M 10-Q · filed 2019-08-02 |
| 2018-03-31 | $473.98M 10-Q · filed 2019-04-29 |
| 2017-12-31 | $598.03M 10-Q/A · filed 2019-11-04 |
| 2017-09-30 | $431.40M 10-Q · filed 2018-10-26 |
| 2017-06-30 | $354.86M 10-Q · filed 2018-08-03 |
| 2017-03-31 | $348.23M 10-Q · filed 2018-04-27 |
| 2016-12-31 | $408.33M 10-K · filed 2019-02-28 |
| 2016-09-30 | $707.35M 10-Q · filed 2017-10-31 |
| 2016-06-30 | $305.97M 10-Q · filed 2017-08-02 |
| 2016-03-31 | $270.45M 10-Q · filed 2017-05-04 |
| 2015-12-31 | $397.04M 10-K · filed 2019-02-28 |
| 2015-09-30 | $376.35M 10-Q · filed 2016-11-03 |
| 2015-06-30 | $440.66M 10-Q · filed 2016-08-08 |
| 2015-03-31 | $900.57M 10-Q · filed 2016-05-02 |
| 2014-12-31 | $875.49M 10-K · filed 2018-02-26 |
| 2014-09-30 | $398.00M 10-Q · filed 2015-11-02 |
| 2014-06-30 | $584.72M 10-Q · filed 2015-08-05 |
| 2014-03-31 | $639.78M 10-Q · filed 2015-05-05 |
| 2013-12-31 | $568.78M 10-K · filed 2017-02-27 |
| 2013-09-30 | $181.56M 10-Q · filed 2014-10-28 |
| 2013-06-30 | $175.44M 10-Q · filed 2014-07-31 |
| 2013-03-31 | $154.38M 10-Q · filed 2014-05-02 |
| 2012-12-31 | $180.53M 10-K · filed 2016-02-29 |
| 2012-09-30 | $181.33M 10-Q · filed 2013-10-28 |
| 2012-06-30 | $177.76M 10-Q · filed 2013-07-29 |
| 2012-03-31 | $82.59M 10-Q · filed 2013-04-29 |
| 2011-12-31 | $46.27M 10-K · filed 2015-03-02 |
| 2011-09-30 | $71.25M 10-Q · filed 2012-10-29 |
| 2011-06-30 | $112.96M 10-Q · filed 2012-08-02 |
| 2011-03-31 | $90.78M 10-Q · filed 2012-04-30 |
| 2010-12-31 | $88.08M 10-K · filed 2014-02-26 |
| 2010-09-30 | $127.54M 10-Q · filed 2011-10-31 |
| 2010-06-30 | $115.78M 10-Q · filed 2011-08-01 |
| 2010-03-31 | $108.96M 10-Q · filed 2011-04-29 |
| 2009-12-31 | $167.17M 10-K · filed 2013-02-26 |
| 2009-09-30 | $191.78M 10-Q · filed 2010-10-29 |
| 2009-06-30 | $200.05M 10-Q · filed 2010-08-04 |
| 2008-12-31 | $222.90M 10-K · filed 2012-02-22 |
| 2007-12-31 | $228.34M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |